Literature DB >> 9266730

Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis.

T L Williams1, N C Day, P G Ince, R K Kamboj, P J Shaw.   

Abstract

The cause of the selective degeneration of motor neurons in amyotrophic lateral sclerosis (ALS) remains unexplained. One potential pathogenetic mechanism is chronic toxicity due to disturbances of the glutamatergic neurotransmitter system, mediated via alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-sensitive glutamate receptors. Functional AMPA receptors consist of various combinations of four subunits (designated GluR1-4). The GluR2 subunit is functionally dominant and renders AMPA receptors impermeable to calcium. Most native AMPA receptors in the mammalian central nervous system (CNS) contain the GluR2 subunit and are calcium impermeable. We have investigated the composition of AMPA receptors expressed on normal human spinal motor neurons by in situ hybridization to determine their likely subunit stoichiometry. Highly significant levels of mRNA were detected for the GluR1, GluR3, and GluR4 subunits. However, GluR2 subunit mRNA was not detectable in this cell group. The absence of detectable GluR2 mRNA in normal human spinal motor neurons predicts that they express calcium-permeable AMPA receptors unlike most neuronal groups in the human CNS. Expression of atypical calcium-permeable AMPA receptors by human motor neurons provides a possible mechanism whereby disturbances of glutamate neurotransmission in ALS may selectively injure this cell group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266730     DOI: 10.1002/ana.410420211

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

Review 1.  Motor neurone disease.

Authors:  P J Shaw
Journal:  BMJ       Date:  1999-04-24

2.  Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1.

Authors:  M D Nguyen; R C Larivière; J P Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  AMPA receptor current density, not desensitization, predicts selective motoneuron vulnerability.

Authors:  W Vandenberghe; E C Ihle; D K Patneau; W Robberecht; J R Brorson
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

4.  Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors.

Authors:  Friedrich Schlesinger; Derk Tammena; Klaus Krampfl; Johannes Bufler
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Chronic electromyograms in treadmill running SOD1 mice reveal early changes in muscle activation.

Authors:  Katharina A Quinlan; Elma Kajtaz; Jody D Ciolino; Rebecca D Imhoff-Manuel; Matthew C Tresch; Charles J Heckman; Vicki M Tysseling
Journal:  J Physiol       Date:  2017-07-05       Impact factor: 5.182

6.  Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons.

Authors:  Shyam D Rao; Hong Z Yin; John H Weiss
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

7.  AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability.

Authors:  W Vandenberghe; W Robberecht; J R Brorson
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 8.  Synaptic control of motoneuronal excitability.

Authors:  J C Rekling; G D Funk; D A Bayliss; X W Dong; J L Feldman
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

9.  Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms.

Authors:  J Roy; S Minotti; L Dong; D A Figlewicz; H D Durham
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.